Editorial: Beyond therapeutic innovation in genitourinary cancers: the unmet need for biologically driven patient selection

1

The therapeutic landscape of genitourinary cancers has transformed with new treatments, yet patient selection remains a challenge.
2

Biomarkers play a crucial role in predicting treatment response, but current options are heterogeneous and insufficient.
3

Tumor biology and microenvironment complexity significantly influence therapeutic outcomes in genitourinary malignancies.
4

Metabolic reprogramming and regulatory molecules like microRNAs are key factors in tumor progression and treatment sensitivity.
5

Future advancements depend on integrative models that combine multi-omics data and dynamic tumor characterization for better patient outcomes.

1